• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

基于纵向磁共振成像的雄激素敏感型前列腺癌异种移植在雄激素暴露和雄激素剥夺条件下血管变化和放射反应的评估。

Longitudinal magnetic resonance imaging-based assessment of vascular changes and radiation response in androgen-sensitive prostate carcinoma xenografts under androgen-exposed and androgen-deprived conditions.

机构信息

Department of Radiation Biology, Institute for Cancer Research, The Norwegian Radium Hospital, Oslo University Hospital, Oslo, Norway.

出版信息

Neoplasia. 2010 Oct;12(10):818-25. doi: 10.1593/neo.10484.

DOI:10.1593/neo.10484
PMID:20927320
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC2950331/
Abstract

Prostate cancer (PCa) patients receive androgen-deprivation therapy (ADT) to reduce tumor burden. However, complete eradication of PCa is unusual, and recurrent disease is evident within approximately 2 years in high-risk patients. Clinical evidence suggests that combining ADT with radiotherapy improves local control and disease-free survival in these patients compared with radiotherapy alone. We investigated whether vascularization of androgen-sensitive PCa xenografts changed after ADT and whether such therapy affected radiation response. CWR22 xenografts received combinations of ADT by castration (CWR22-cas) and 15 Gy of single-dose irradiation. At a shortest tumor diameter of 8 mm, vascularization was visualized by dynamic contrast-enhanced magnetic resonance imaging before radiation and 1 and 9 days after radiation. Voxel-wise quantitative modeling of contrast enhancement curves extracted the hemodynamic parameter K(trans), reflecting a combination of permeability, density, and blood flow. Tumor volumes and prostate-specific antigen (PSA) were monitored during the experiment. The results showed that K(trans) of CWR22-cas tumors 36±4 days after ADT was 47.1% higher than K(trans) of CWR22 tumors (P = .01). CWR22-cas tumors showed no significant changes in K(trans) after radiation, whereas K(trans) of CWR22 tumors at day 1 decreased compared with pretreatment values (P = .04) before a continuous increase from day 1 to day 9 followed (P = .01). Total PSA in blood correlated positively to tumor volume (r = 0.59, P < .01). In conclusion, androgen-exposed xenografts demonstrated radiation-induced reductions in vascularization and tumor volumes, whereas androgen-deprived xenografts showed increased vascularization and growth inhibition, but no significant additive effect of radiation.

摘要

前列腺癌 (PCa) 患者接受雄激素剥夺疗法 (ADT) 以减少肿瘤负担。然而,PCa 完全消除并不常见,高风险患者中大约 2 年内会出现复发性疾病。临床证据表明,与单独放疗相比,ADT 联合放疗可提高这些患者的局部控制率和无病生存率。我们研究了 ADT 后雄激素敏感型 PCa 异种移植物的血管生成是否发生变化,以及这种治疗是否影响放射反应。CWR22 异种移植物接受去势 (CWR22-cas) 和 15 Gy 单次剂量照射的 ADT 联合治疗。在最短肿瘤直径为 8mm 时,在放疗前和放疗后 1 天和 9 天通过动态对比增强磁共振成像观察血管生成。从对比增强曲线中提取反映渗透性、密度和血流综合作用的血流动力学参数 K(trans)的体素定量模型。在实验过程中监测肿瘤体积和前列腺特异性抗原 (PSA)。结果表明,ADT 后 36±4 天的 CWR22-cas 肿瘤的 K(trans)比 CWR22 肿瘤的 K(trans)高 47.1% (P =.01)。CWR22-cas 肿瘤在放疗后 K(trans)无明显变化,而 CWR22 肿瘤在第 1 天的 K(trans)与预处理值相比下降 (P =.04),随后从第 1 天到第 9 天持续增加 (P =.01)。血液中的总 PSA 与肿瘤体积呈正相关 (r = 0.59,P <.01)。总之,暴露于雄激素的异种移植物显示出放射诱导的血管生成和肿瘤体积减少,而雄激素剥夺的异种移植物显示出血管生成增加和生长抑制,但放射无显著的附加作用。

相似文献

1
Longitudinal magnetic resonance imaging-based assessment of vascular changes and radiation response in androgen-sensitive prostate carcinoma xenografts under androgen-exposed and androgen-deprived conditions.基于纵向磁共振成像的雄激素敏感型前列腺癌异种移植在雄激素暴露和雄激素剥夺条件下血管变化和放射反应的评估。
Neoplasia. 2010 Oct;12(10):818-25. doi: 10.1593/neo.10484.
2
Vascular responses to radiotherapy and androgen-deprivation therapy in experimental prostate cancer.实验性前列腺癌中放射治疗和雄激素剥夺治疗的血管反应。
Radiat Oncol. 2012 May 23;7:75. doi: 10.1186/1748-717X-7-75.
3
Combination antiangiogenic and androgen deprivation therapy for prostate cancer: a promising therapeutic approach.联合抗血管生成与雄激素剥夺疗法治疗前列腺癌:一种有前景的治疗方法。
Clin Cancer Res. 2004 Dec 15;10(24):8728-34. doi: 10.1158/1078-0432.CCR-04-0902.
4
Metastatic phenotype in CWR22 prostate cancer xenograft following castration.去势后CWR22前列腺癌异种移植瘤中的转移表型
Prostate. 2016 Mar;76(4):359-68. doi: 10.1002/pros.23127. Epub 2015 Dec 8.
5
Fibroblasts prolong serum prostate-specific antigen decline after androgen deprivation therapy in prostate cancer.在前列腺癌中,成纤维细胞可延长雄激素剥夺治疗后血清前列腺特异性抗原的下降时间。
Lab Invest. 2016 Mar;96(3):338-49. doi: 10.1038/labinvest.2015.136. Epub 2015 Dec 7.
6
Hypoxia-independent downregulation of hypoxia-inducible factor 1 targets by androgen deprivation therapy in prostate cancer.雄激素剥夺治疗前列腺癌中缺氧非依赖的缺氧诱导因子 1 靶向下调。
Int J Radiat Oncol Biol Phys. 2013 Nov 15;87(4):753-60. doi: 10.1016/j.ijrobp.2013.07.023. Epub 2013 Sep 10.
7
CWR22: the first human prostate cancer xenograft with strongly androgen-dependent and relapsed strains both in vivo and in soft agar.CWR22:首个在体内和软琼脂中均具有强烈雄激素依赖性和复发菌株的人前列腺癌异种移植瘤。
Cancer Res. 1996 Jul 1;56(13):3042-6.
8
Androgen withdrawal inhibits tumor growth and is associated with decrease in angiogenesis and VEGF expression in androgen-independent CWR22Rv1 human prostate cancer model.雄激素撤除抑制肿瘤生长,并与雄激素非依赖性CWR22Rv1人前列腺癌模型中血管生成及VEGF表达的降低相关。
Anticancer Res. 2004 Jul-Aug;24(4):2135-40.
9
Metabolic response of the CWR22 prostate tumor xenograft after 20 Gy of radiation studied by 1H spectroscopic imaging.通过氢谱成像研究20 Gy辐射后CWR22前列腺肿瘤异种移植的代谢反应。
Clin Cancer Res. 2003 Oct 1;9(12):4529-36.
10
Dysregulated expression of androgen-responsive and nonresponsive genes in the androgen-independent prostate cancer xenograft model CWR22-R1.雄激素非依赖性前列腺癌异种移植模型CWR22-R1中雄激素反应性和非反应性基因的表达失调。
Cancer Res. 2000 Nov 1;60(21):6134-41.

引用本文的文献

1
Radiation treatment monitoring using multimodal functional imaging: PET/CT ((18)F-Fluoromisonidazole & (18)F-Fluorocholine) and DCE-US.使用多模态功能成像进行放射治疗监测:PET/CT((18)F-氟米索硝唑和(18)F-氟胆碱)及动态对比增强超声
J Transl Med. 2015 Dec 18;13:383. doi: 10.1186/s12967-015-0708-5.
2
Overcoming intratumor heterogeneity of polygenic cancer drug resistance with improved biomarker integration.通过改进生物标志物整合克服多基因癌症耐药性的肿瘤内异质性。
Neoplasia. 2012 Dec;14(12):1278-89. doi: 10.1593/neo.122096.
3
Vascular responses to radiotherapy and androgen-deprivation therapy in experimental prostate cancer.实验性前列腺癌中放射治疗和雄激素剥夺治疗的血管反应。
Radiat Oncol. 2012 May 23;7:75. doi: 10.1186/1748-717X-7-75.
4
Dynamic contrast-enhanced MRI in clinical trials of antivascular therapies.动态对比增强 MRI 在抗血管治疗临床试验中的应用。
Nat Rev Clin Oncol. 2012 Feb 14;9(3):167-77. doi: 10.1038/nrclinonc.2012.2.
5
The interconnectedness of cancer cell signaling.癌细胞信号的相互关联性。
Neoplasia. 2011 Dec;13(12):1183-93. doi: 10.1593/neo.111746.
6
Liposomal doxorubicin improves radiotherapy response in hypoxic prostate cancer xenografts.脂质体阿霉素可提高低氧前列腺癌异种移植模型对放疗的反应。
Radiat Oncol. 2011 Oct 7;6:135. doi: 10.1186/1748-717X-6-135.
7
Early prediction of response to radiotherapy and androgen-deprivation therapy in prostate cancer by repeated functional MRI: a preclinical study.通过重复功能磁共振成像预测前列腺癌对放疗和雄激素剥夺治疗的早期反应:一项临床前研究。
Radiat Oncol. 2011 Jun 8;6:65. doi: 10.1186/1748-717X-6-65.
8
Dinosaurs and ancient civilizations: reflections on the treatment of cancer.恐龙与古代文明:癌症治疗的反思。
Neoplasia. 2010 Dec;12(12):957-68. doi: 10.1593/neo.101588.

本文引用的文献

1
Dynamic contrast-enhanced magnetic resonance imaging of vascular changes induced by sunitinib in papillary renal cell carcinoma xenograft tumors.舒尼替尼诱导的乳头状肾细胞癌异种移植瘤血管变化的动态对比增强磁共振成像
Neoplasia. 2009 Sep;11(9):910-20. doi: 10.1593/neo.09618.
2
Noninvasive multimodality imaging of the tumor microenvironment: registered dynamic magnetic resonance imaging and positron emission tomography studies of a preclinical tumor model of tumor hypoxia.肿瘤微环境的非侵入性多模态成像:肿瘤缺氧临床前肿瘤模型的配准动态磁共振成像和正电子发射断层扫描研究
Neoplasia. 2009 Mar;11(3):247-59, 2p following 259. doi: 10.1593/neo.81360.
3
Endocrine treatment, with or without radiotherapy, in locally advanced prostate cancer (SPCG-7/SFUO-3): an open randomised phase III trial.局部晚期前列腺癌的内分泌治疗(联合或不联合放疗)(SPCG-7/SFUO-3):一项开放随机III期试验
Lancet. 2009 Jan 24;373(9660):301-8. doi: 10.1016/S0140-6736(08)61815-2. Epub 2008 Dec 16.
4
Hypoxia in prostate cancer: a powerful shield against tumour destruction?前列腺癌中的缺氧:抵御肿瘤破坏的强大盾牌?
Cancer Treat Rev. 2008 Jun;34(4):313-27. doi: 10.1016/j.ctrv.2008.01.006. Epub 2008 Mar 10.
5
Construction of a modified capacitive overlap MR coil for imaging of small animals and objects in a clinical whole-body scanner.一种用于在临床全身扫描仪中对小动物和物体进行成像的改良电容式重叠磁共振线圈的构建。
Phys Med Biol. 2007 Nov 21;52(22):N513-22. doi: 10.1088/0031-9155/52/22/N02. Epub 2007 Oct 26.
6
Correlation of MRI biomarkers with tumor necrosis in Hras5 tumor xenograft in athymic rats.无胸腺大鼠Hras5肿瘤异种移植中MRI生物标志物与肿瘤坏死的相关性
Neoplasia. 2007 May;9(5):382-91. doi: 10.1593/neo.07145.
7
Effect of carbogen breathing on the radiation response of a human glioblastoma xenograft: analysis of hypoxia and vascular parameters of regrowing tumors.卡波金呼吸对人胶质母细胞瘤异种移植瘤辐射反应的影响:对再生长肿瘤的缺氧和血管参数的分析
Strahlenther Onkol. 2006 Jul;182(7):408-14. doi: 10.1007/s00066-006-1545-5.
8
Radiation therapy combined with hormone therapy for prostate cancer.放射治疗联合激素治疗前列腺癌。
Semin Radiat Oncol. 2006 Jan;16(1):20-8. doi: 10.1016/j.semradonc.2005.08.003.
9
Angiogenesis and prostate cancer tumor growth.血管生成与前列腺癌肿瘤生长。
J Cell Biochem. 2004 Jan 1;91(1):125-50. doi: 10.1002/jcb.10772.
10
Metabolic response of the CWR22 prostate tumor xenograft after 20 Gy of radiation studied by 1H spectroscopic imaging.通过氢谱成像研究20 Gy辐射后CWR22前列腺肿瘤异种移植的代谢反应。
Clin Cancer Res. 2003 Oct 1;9(12):4529-36.